Metformin treatment for patients with hand osteoarthritis: protocol for the multicentre, randomised, placebo-controlled METRO trial.
Kasper Staberg Madsen, Marius Henriksen, Anna Døssing...
https://pubmed.ncbi.nlm.nih.gov/40139705/Actively Recruiting
Led by Marius Henriksen · Updated on 2025-02-27
150
Participants Needed
1
Research Sites
17 weeks
Total Duration
Researchers are evaluating the use of metformin as a potential treatment for hand osteoarthritis symptoms. This randomized, placebo-controlled Phase 3 trial aims to compare metformin, given at up to 2 grams daily for 16 weeks, with a placebo to assess its impact on finger pain and other hand osteoarthritis symptoms. The study is led by Marius Henriksen and focuses on adults aged 18 years and older who have hand osteoarthritis with moderate finger pain. Participants receive metformin starting at 500 mg once daily with breakfast, with the dose increasing by 500 mg each week until reaching 2 grams per day or the maximum tolerated dose, divided into two doses with meals. The treatment period, including dose escalation, lasts 16 weeks. The placebo group receives tablets identical to metformin but without the active drug. Both groups are monitored throughout the study period. During the trial, participants will be assessed for finger pain, hand function, thumb base pain, hand pain overall, tender joint counts, patient global assessment, quality of life via the EQ-5D scale, hand strength, and treatment response after 16 weeks. Safety and eligibility will be carefully monitored through clinical evaluations and blood tests. The total involvement spans the 16-week treatment period, during which participants will attend scheduled visits for these evaluations.
CONDITIONS
Metformin Treatment of Patients with Hand Osteoarthritis
K
Kasper Staberg Madsen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Marius Henriksen
Lead Sponsor
You may qualify if you...
You will not qualify if you...
History or current signs of joint diseases like rheumatoid arthritis, gout, or psoriatic arthritis
Psoriasis
Known malignancy except successfully treated skin carcinoma
Drug or alcohol abuse in the last year
Existing nerve entrapment syndromes such as carpal tunnel syndrome
Known diabetes
Generalized pain syndromes such as fibromyalgia
Known peripheral neuropathies
Known allergies to the study interventions
Gastric bypass or other malabsorption syndromes
Recent changes in weight loss or osteoporosis medication
Conditions or impairments that make study participation unsuitable
Recent hand surgery or surgical treatment of thumb base osteoarthritis
Use of systemic corticosteroids above specified dose recently
Treatment with denosumab
Participation in experimental drug or device studies recently
Recent intra-articular treatments of target hand joints
Current use of opioids
Planning to start other treatments for hand osteoarthritis during study
Planned CT scans with iodine contrast
Scheduled surgeries affecting study participation
Pregnancy or planned pregnancy during and after study period
Insufficient contraception use during and after study
Breastfeeding
Specific blood test abnormalities including positive anti-cyclic citrullinated peptide, reduced kidney function, vitamin B12 deficiency, or elevated Hba1c levels
Surgical sterilization or postmenopausal status as defined for female participants
Surgical sterilization for male participants (vasectomy)
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 16 weeks
Participants receive metformin or placebo treatment. The metformin dose starts at 500 mg once daily and is increased weekly until 2 g/day or the maximum tolerated dose is reached. The total treatment duration including dose titration is 16 weeks.
Regular visits during treatment period as scheduled by study staff
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kasper Staberg Madsen, Marius Henriksen, Anna Døssing...
https://pubmed.ncbi.nlm.nih.gov/40139705/Marius Henriksen
Lead Sponsor